ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a media release dated July 28, 2007, titled "Orchid's Managing Director honoured with Doctorate by leading university". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_30072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated July 20, 2007, titled "Orchid receives US FDA approval for its Cefdinir ANDAs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_20072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated July 19, 2007, titled "Orchid Q1 FY 2007-08 net profit surges by 252% to Rs 51 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_19072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 25176.97 lacs for quarter ending on 30-JUN-2007 against Rs. 21264.9 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4858.94 lacs for the quarter ending on 30-JUN-2007 against Rs. 1083.24 lacs for the quarter ending on 30-JUN-2006.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 23819.64 lacs for quarter ending on 30-JUN-2007 against Rs. 20170.98 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5129.8 lacs for the quarter ending on 30-JUN-2007 against Rs. 1459.09 lacs for the quarter ending on 30-JUN-2006.

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the notice of the Annual General Meeting of the members of the Company to be held on July 19, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_AGM_09072007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange that: "Orchid has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for CEfepime injection. The product is available in three dosage strength 500 mg/vial, 1 gram/vial, and 2 grams/vial". A copy of the press release dated June 21, 2007, titled "Orchid receives US FDA approval for its Cefepime ANDA" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChemPharma_PR_21062007.

Orchid Chemicals Ltd has informed the Exchange that the Annual General Meeting of the Company has been proposed to be held on July 19, 2007. The dates of closure of Register of Members for the purpose of Annual General Meeting and for payment of dividend has been fixed by the Board from July 15, 2007 to July 19, 2007 (both days inclusive).

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated June 15, 2007, titled "Orchid forays into the non-antibiotic generic formulations segment". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChemnPharma_PR_150607.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange that : " a section of the workmen at Orchid's Alathur - API Plant are on an illegal strike, demanding increase in wages & benefits. The Management is working very closely with the State Government Labour Department to resolve the issues.The operations are being carried on with the majority of personnel attending the duties.

Orchid Chemicals Ltd has informed the Exchange on May 04, 2007 that "The Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited at their meeting held on May 3, 2007 have allotted 6,085 equity shares of Rs. 10 each (375 equity shares at an adjusted price of Rs. 162.24 per share, 210 equity shares at an adjusted price of Rs. 168 per share and 5,500 equity shares at an adjusted price of Rs. 200.44 per share) to the emplyoees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment. Consequent to t

Orchid Chemicals Ltd has informed the Exchange regarding a press release dated May 03, 2007, titled "Orchid's turnover rises to Rs.934 crore during FY 2006-07- Net profit increases to Rs 97 crore". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_PR_03052007.zip target=NEW> For more details click here.</a>

Orchid Chemicals Ltd has informed the Exchange that the Board of Directors of the Company at its meeting held on May 03, 2007 have recommended a dividend of 30% (Rs.3/- per share) on the equity share of Rs.10/- each.

Orchid Chemicals Ltd has informed the Exchange that: "Orchid's wholly-owned Drug Discovery subsidiary in Chennai, Orchid Research Laboratories Ltd (ORLL) has been conferred the Frost & Sullivan Award for Partner of Choice in Contract Research - Collaborative Drug Discovery". A copy of the press release issued by the Company dated April 30, 2007, titled "Orchid's drug discovery subsidiary (Orchid Research Labs) awarded Partner of Choice award by Frost & Sullivan" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (

Orchid Chemicals Ltd has informed the Exchange that "Orchid has received the approval from the Canadian TPD (Therapeutic Product Directorate) for 2 of its ANDS (Abbreviated New Drug Submission) applications. These approvals correspond to two generic formulations, Cefoxitin and Ceftriaxone". Further the Company has submitted a copy of press release dated April 03, 2007, titled "Orchid to foray into the Canadian generic formulations market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extra

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange "that the Board of Director have forfeited the 10% of the share price amount paid, aggregating to Rs. 805.54 lakhs, by Mrs. R. Vijayalakshmi (Promoter) and Dr. M R Girinath (Promoter Group) on account of the non-conversion of the 35,60,000 share warrants into equity within the stipulated period of 18 months from the date of allotment of warrants (i.e. on or before February 01, 2007)".

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that: "The Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited held on February 27, 2007 has allotted Zero Coupon Foreign Currency Convertible Bonds due 2012 (FCCBs), aggregating US$ 175 million (US $ one hundred and seventy five million only). The above bonds are listed on the Singapore Stock Exchange from February 28, 2007". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/C

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that: "The Allotment committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited on March 01, 2007, have allotted 50,00,000 (fifty lakh only) Warrants convertible into equity to the following persons. Each warrant is convertible into one equity share of Rs.10 each within eighteen months from the date of Allotment, at a price of Rs.202.58 (Rupees two hundred and two and paise fifty eight only). 1) Name of the Allottee: Promoter - Ms.R.Divya (D/o Shri K Raghavendra Rao, Managing Director & Promoter of Orchid C

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated February 25, 2007, titled "Orchid's Zero coupon FCCB issue to retire foreign currency debt and support other business purposes". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/orchid_press1_260207.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the shareholders of the Company have approved the issue of 50,00,000 Warrants on a preferential basis to the promoters / Promoter Group(s) / relatives of the Promoters each convertible into one equity share of the Company of nominal value of Rs. 10/- each at a premium of Rs. 192.58, at an Extraordinary General Meeting (EGM) held on February 14, 2007. Further the Company has submitted a copy of the resolution passed by the Shareholders at the EGM the details of the same shall be available on the NSE website (http://www.nseind

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the shareholders of the Company have approved the issue of 50,00,000 Warrants on a preferential basis to the promoters / Promoter Group(s) / relatives of the Promoters each convertible into one equity share of the Company of nominal value of Rs. 10/- each at a premium of Rs. 192.58, at an Extraordinary General Meeting (EGM) held on February 14, 2007. Further Company has submitted a copy of resolution passed by the Shareholders at the EGM. The details of the same shall be available on the NSE website (http://www.nseindia.com

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that "Pursuant to the approval received from the shareholders for raising funds in the overseas markets, Orchid Chemicals & Pharmaceuticals Ltd., has placed a zero coupon Foreign Currency Convertible Bond (FCCB) offering of USD 175 million with a greenshoe option of USD 25 million, aggregating to USD 200 million. The bonds are convertible at an initial conversion price of Rs 348.34 which represents a premium of 30% over Monday's (February 12, 2007) closing price of the company's scrip on the NSE (Rs 267.95). This works out to a c

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has entered into a licensing and distribution agreement with the international generic pharmaceuticals company Actavis, Iceland for marketing 9 of Orchid's cephalosporin generic formulations in Europe. A copy of press release in this regard dated February 01, 2007, titled �Orchid in a new licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the Notice of the Extraordinary General Meeting to be held on Wednesday, February 14, 2007". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_EGM_2401020076.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a media release dated January 22,2007, titled "Orchid's Betalactam API facility at Aurangabad approved by the UK MHRA". A copy of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_Press_220107.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange "that the following has been considered at a meeting of the Board of Directors of the Company held on Friday, January 19, 2007:- (a) Issue of Warrants - Issue of 5 million Warrants, convertible into Equity Share to the Promoter(s)/Promoter Group(s)/Relatives of Prmoters in accordance with the SEBI Guidelines for Preferential Issue in lieu of 3.56 million unsubscribed warrants as on date. (b) Extraordinary General Meeting - An Extraordinary General Meeting of the Company has been proposed to be held on Wednesday, February 14, 2007

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated January 19,2007, titled "Orchid registers turnover of Rs 239 crore during Q3 FY 2006-07; Net profit stands at Rs 28 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_PR_19012007.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has signed a contract with Biovitrum to undertake medicinal chemistry work to support certain drug discovery activities of Biovitrum AB (publ). A press release dated October 30,2006, titled "Orchid signs deal with Biovitrum in drug discovery field" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidCh_PR_30102006.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated October 19,2006, titled "Orchid's Q2 FY07 net profit rises to Rs 29 crore". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/OrchidChem_PR_19102006.zip target=NEW> For more details click here.</a>

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefadroxil 500 mg Capsules and 1 g Tablets. The Company has also submitted a copy of press release, dated September 22, 2006, titled "Orchid receives USFDA approvals for Cefadroxil ANDAs". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Orchid_2

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid has received the approvals from the UK regulator, Medicines and Healthcare products Regulatory Agency (MHRA) for sterile cephalosporin Finished Dosage Form (formulations) and Active Pharmaceutical Ingredients (APIs) facilities located near Chennai in Irungattukottai and Alathur respectively. The Company has also submitted a copy of press release, dated September 21, 2006, titled "Orchid's Formulation and API facilities approved by the UK MHRA." The details of the press release shall be available on the NSE website (ht

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Dr. Francis Pinto, Director has resigned from the directorship of Orchid Chemicals & Pharmaceuticals Limited with effect from August 21, 2006.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Company has received the formal approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Cefotaxime for injection in various dosage forms. A copy of the press release dated August 16, 2006, titled " Orchid receives USFDA approvals for Cefotaxime Injection ANDAs -Mature genertic product with limited competition "shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Compensation Committee of the Board at their meeting held on August 12,2006 has approved the following : a) The issue of 6,10,000 stock options under ORCHID-ESOP 2005 Scheme. The stock options are convertible into equity shares of Rs.10/- each at a price of Rs. 193.25 per share. b) To reprice the 3,00,000 options granted on April 28,2006 at a price of Rs. 193.25 per share subject to the shareholders approval and other consents as may be required.

Orchid Chemicals & Pharmaceuticals Ltd has submitted to the Exchange a copy of the Proceedings of the AGM of the Company held on June 02, 2006. A copy of the proceedings shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Orchid and Bexel Pharmaceuticals Inc. have reached understanding by which Orchid would extend its ownership in Bexel from the current 74% to 100%. Further, a copy of the press release dated July 31,2006, titled "Orchid undertakes structural consolidation of global discovery research" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a media release, titled "Orchid Q1 FY 2006-07 net profit up by 99%". The details of the media release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated July 12,2006, titled "Orchid receives USFDA approval for Cephalexin oral suspension ANDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Mr. Raj RajKumar, Director has acquired 13,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.on June 13, 2006. The mode of acquisition is Market Purchase and the shareholding of Mr. Raj RajKumar after the said acquisition is 70,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that Mr. Raj RajKumar, Director has acquired 7,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.on June 08, 2006. The mode of acquisition is Market Purchase and the shareholding of Mr. Raj RajKumar after the said acquisition is 57,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that :- 1) Dr. I Seetharam Naidu, Director has acquired 9,000 shares of Orchid Chemicals & Pharmaceuticals Ltd.on May 19, 2006 and May 22, 2006. The mode of acquisition is Market Purchase and the shareholding of Dr. I Seetharam Naidu after the said acquisition is 3,84,280 shares aggregating to 0.58% of the share capital of Orchid Chemicals & Pharmaceuticals Ltd.. 2) Mr. Raj Rajkumar, Director has acquired 10,000 shares on May 19, 2006 of Orchid Chemicals & Pharmaceuticals Ltd.. The mode of acquisition is Market Purchase and the s

(b) Allotment of equity shares to Employees under ORCHID-ESOP 99 scheme. 3,015 equity shares of Rs.10 each (600 equity shares at an adjusted price of Rs.162.24 per share, 1,177 equity shares at an adjusted price of Rs.168 per share and 1,238 equity shares at an adjusted price of Rs.200.44 per share) were allotted to the employees under ESOP 1999 Scheme. The equity shares allotted will be locked in for a period of one year from the date of Allotment. (c) Consequent to these allotments, the paid-up capital of the company has increased from Rs. 65,77,37,260 to Rs. 65,81,17,410.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment committee of the Board of Directors of Orchid on May 31, 2006 have allotted the below mentioned equity shares;(a) Allotment of equity shares to Promoter / Promoter Group(s) - Conversion of Warrants-35, 000 (thirty five thousand only) equity shares of Rs.10/- each arising out of the conversion of 35,000 warrants pursuant to the approval given by the members of the Company at the Annual General Meeting held on July 18, 2005. These shares have been issued at an adjusted price of Rs.226.28 (Rupees two hundred and t

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that at a meeting of the Board of Directors of the Company held on May 04, 2006, considered :- 1) Raising of long term resources:- It may be recalled that the shareholders had earlier approved the raising by the company of funds in the overseas market upto US$ 75 million by way of issue of FCCBs and US$ 115 million by way of issue of GDRs (US$ 190 million, inclusive of green shoe option in total). These resolutions were considered and approved in April 2004 and July 2005 respectively, prior to the bonus issue which was approved i

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Annual General Meeting of the Company has been proposed to be held on June 02, 2006. The dates of closure of Register of Members for the purpose of Annual General Meeting & payment of dividend has been fixed by the Board from June 01, 2006 to June 02, 2006 (both days inclusive).

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the BoDs at its meeting held on April 28, 2006 have recommended a dividend of 30% (Rs.3/- per share) on the equity shares of Rs.10/- each.

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited at thier meeting held on April 28, 2006 has alloted 737,325 equity shares of Rs.10 each of the Company on conversion of Zero Coupon Foriegn Currency Convertible Bonds to the extent of US $ 4,000,000. These shares have been issued at a price of Rs. 243.80 per share (price equivalent to US $ 5.425 per share) in accordance with the terms of the FCCBs issue made by the Company during November 2005. Further, the allotment Committee of

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited at their meeting held on April 18, 2006 has allotted 414,744 equity shares of Rs.10 each of the company on conversion of Zero Coupon Foreign currency convertible bonds to the extent of US$ 2,250,000. These shares have been issued at a price of Rs. 243.80 per share (price equivalent to US$ 5.425 per share) in accordance with the terms of the FCCB issue made by the company during November 2005. The company has further informed that

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that that the Allotment Committee of the Board of Directors of the Company at their meeting held on March 31, 2006 has allotted 652,531 equity shares of Rs.10 each of the Company on conversion of Zero Coupon Foreign Currency Convertible Bonds to the extent of US$ 3,540,000. These shares have been issued at a price of Rs.243.80 per share (price equivalent to US$ 5.425 per share) in accordance with the terms of the FCCB issue made by the Company during November 2005. Further, the Allotment Committee of the Board of Orchid at the,

Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that the Allotment Committee of the Board of Directors of Orchid Chemicals & Pharmaceuticals Limited at their meeting held on March 20, 2006 have allotted a. 92,165 equity shares of Rs.10 each arising out of conversion of Zero Coupon Foreign Currency Convertible Bonds aggregating US$ 500,000 to M/s. Plexus Fund Limited and b. 737,324 equity shares of Rs.10 each arising out of conversion of Zero Coupon Foreign Currency Convertible Bonds aggregating US$ 4,000,000 to M/S. Goldman Sachs Investments (Mauritius) I Ltd. These shares hav